The present-day challenges, including constrained resources, disease severity, limited patient access, and a lack of available knowledge in rare diseases, necessitate the discovery of innovative solutions to hasten orphan drug development.
With the enforcement of the 1983 Orphan Drug Act (ODA), manufacturers are obliged to scale production to treat rare/orphan diseases, leading to a drastic advancement in the landscape of orphan drugs. Novel therapies aimed at treating these uncommon diseases are paramount to fulfilling the unmet needs of patients.
The 4th Annual MarketsandMarkets Orphan Drugs and Rare Diseases Conference, to be held on October 9–10 in London, UK, aims to provide a valuable and broad platform to discuss recent advances in the development of life-saving therapies, critical issues, and strategies to enhance orphan drug development in near future. The conference will bring together scientists, researchers, entrepreneurs, academicians, medical officials, and technologists across the globe to discuss the newest findings in the areas of rare diseases and orphan drugs, helping to shape present and upcoming challenges in drug analysis. It gives participants the chance to interact with industry peers and participate in this scientific conference while staying informed about the most recent developments in the study of rare diseases.
Industry: Pharma/Therapeutic Companies/Start Up’s
Designations: CEO, CSO, CMO, COO, President, Vice President, Director, Head of Department, Executive Leader, Senior Manager, Manager, Principle Scientist.
Academic: Universities, Research institutes – Professors & Researchers.